Merck Gets Positive EU CHMP Opinion for WELIREG®
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive…
Category News
Read MoreMerck Gets Positive EU CHMP Opinion for WELIREG®
Geron’s RYTELO™ Receives Positive CHMP Opinion for Lower-Risk MDS
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on blood cancer treatments, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
NeoGenomics Study Highlights ctDNA as a Predictive Tool for High-Risk Melanoma
NeoGenomics, Inc. (NASDAQ: NEO), a leader in oncology testing services, has announced the publication of a new study in ESMO Open. The study highlights the potential of circulating tumor DNA…
RevBio Gets FDA Approval to Expand Trial and CMS Reimbursement for Regenerative Bone Adhesive
RevBio, Inc. announced that it has received FDA approval to expand its ongoing clinical trial to use TETRANITE®, its bone adhesive biomaterial, for immediate cranial flap fixation. Additionally, the company…
Sapio Sciences: Boosting Research and Diagnostics with Science-Aware AI
Sapio Sciences, the science-aware™ lab informatics platform, has unveiled the exciting speaker lineup and agenda for SapioCon 2025. Set for February 26–28, 2025, at the Fort Lauderdale Marriott Harbor Beach…
SABCS 2024: New Data on Breast Cancer Index® Test for Minimal Recurrence Risk
Four new studies on the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these, preliminary data will be shared exploring…
Epcoritamab Combination Therapy Shows High Response Rates in R/R Follicular Lymphoma
Genmab A/S has shared new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) for treating relapsed…
Datopotamab Deruxtecan Shows Promise in EGFR-Mutated NSCLC
A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials demonstrated that datopotamab deruxtecan (Dato-DXd) achieved significant clinical responses in patients with previously treated advanced or metastatic…
MaaT Pharma Treats First U.S. Patient with MaaT013 for Acute GvHD at City of Hope
MaaT Pharma, a clinical-stage biotechnology company specializing in Microbiome Ecosystem Therapies™ (MET) to improve cancer patient survival, announced the first treatment in the United States of a patient with acute…
VSee Health and AbundaBox Launch AbundaLife™ to Revolutionize Family Health Record Management
VSee Health, Inc. (Nasdaq: VSEE), a leader in telehealth solutions known for its scalable technology and clinical expertise, has partnered with AbundaBox to launch AbundaLife™, an innovative health record management…
Exai Bio Appoints Karen E. Knudsen to Board of Directors
Exai Bio, a leading RNA- and AI-based liquid biopsy company, has announced the appointment of Karen E. Knudsen, MBA, PhD, to its board of directors. Knudsen, the former CEO of…
OnMed to Debut at CES 2025, Revolutionizing Healthcare Access for Underserved Communities
OnMed, a leading tech-enabled hybrid care company, is set to debut its innovative OnMed CareStation at CES 2025 in Las Vegas, Nevada. This breakthrough solution is transforming how underserved communities…